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Abstract 
5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl)]-2,3-dimethoxybenzamide 1 is a 
potent and selective σ2 receptor ligand suitable for further development. A series of new analogues, 
incorporating a variety of isoquinoline and carboxylic acid moieties, linked together with either a linear or 
cyclic amine spacer have been synthesised and assessed for their σ1/σ2 binding affinity and selectivity. 
Compounds with a rigid piperidine spacer gave Ki values for the σ2 receptor between 8.7–845 nM. 
Changing the configuration of the methoxy groups on the isoquinoline moiety resulted in molecules with 
σ2Ki values of 4.4–133 nM whereas varying the length and flexibility of the carbon spaces gave σ2Ki 
values 0.88–15.0 nM, some of the most active, selective σ2 ligands to date. Thus, the flexibility and 
length of the carbon linker and the carboxylic acid moiety are confirmed to be key to the exceptional 
binding affinity and selectivity for this active series. Additionally, the incorporation of a halogen on 
selected carboxylic acid moieties provided a convenient strategy for the introduction of a radiohalogen for 
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5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl)]-2,3-dimethoxybenzamide 1 is 
a potent and selective σ2 receptor ligand suitable for further development. A series of new analogues, 
incorporating a variety of isoquinoline and carboxylic acid moieties, linked together with either a 
linear or cyclic amine spacer have been synthesised and assessed for their σ1/σ2 binding affinity and 
selectivity. Compounds with a rigid piperidine spacer gave Ki values for the σ2 receptor between 8.7-
845 nM. Changing the configuration of the methoxy groups on the isoquinoline moiety resulted in 
molecules with σ2 Ki values of 4.4-133 nM whereas varying the length and flexibility of the carbon 
spaces gave σ2 Ki values 0.88-15.0 nM, some of the most active, selective σ2 ligands to date. Thus, the 
flexibility and length of the carbon linker and the carboxylic acid moiety are confirmed to be key to the 
exceptional binding affinity and selectivity for this active series. Additionally, the incorporation of a 
halogen on selected carboxylic acid moieties provided a convenient strategy for the introduction of a 
radiohalogen for applications in pharmacological and imaging studies. 
Introduction 
Sigma (σ) receptors are a distinct non-opioid, class of receptors that are located in the central nervous 
system as well as in a variety of peripheral tissues and organs.1 These receptors are unique proteins 
located in plasma, mitochondrial and endoplasmic reticulum membranes of tissue derived from brain, 
kidney, liver, immune, endocrine and reproductive organs.2 Based on drug-binding profiles and 
specific pharmacological characteristics of -receptor ligands, two distinct receptor subtypes denoted 
sigma-1 (σ1) and sigma-2 (σ2) have been identified with molecular weights of ~25 kDa (σ1), and ~21.5 
kDa (σ2).
3 The σ1-receptor has recently been identified as a unique ligand-regulated molecular 
chaperone in the endoplasmic reticulum of cells involved in the regulation and modulation of voltage-
regulated and ligand-gated ion channels, including Ca2+, K+, Na+, Cl-, and SK channels, and NMDA 
and IP3 receptors.4 The findings that neuroactive steroids bind with moderate affinity to σ1 sites, 
suggest that σ1 receptors may modulate the activity of GABA and NMDA receptors in the CNS.
5 
These observations have rekindled interest in assessing their potential role in inhibiting or potentiating 
ion channels with implications in many neurological diseases, amnesia, pain, depression, 
schizophrenia, and neuroprotection.6  
 
The discovery of the presence of σ1 and σ2 receptors in many human and rodent tumours has opened 
new possibilities in the area of cancer research, particularly the involvement of σ2 receptors.
7 In an 
initial screening of human brain tumours, σ receptors were detected in 15 of 16 tumors examined. 
Strong receptor expression was observed in a brain metastasis from a lung adenocarcinoma and in a 
human neuroblastoma passaged in nude mice8, whereas a 2-to-5-fold overexpressed in renal and colon 
carcinomas9 was also found. Observations that a higher number of binding sites was observed for the 
non-subtype-selective σ agonist [3H]1,3-di-o-tolylguanidine ([3H]DTG) than for the σ1-subtype 
selective agonist [3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ([3H]3-PPP) in renal and colon 
carcinomas18 cell lines, suggested that the σ2 receptor is more abundant than the σ1 subtype. However, 
immunocytochemical staining did detect σ1 receptors in the majority of human primary breast 
carcinomas, particularly in tumours with a positive progesterone receptor status.10  
 
Over-expression of σ2 receptors has been observed in primary colon cancers, renal carcinomas and 
 
sarcomas9 and pancreatic cancers.11 Recently it was shown that the σ2 receptor density in proliferative 
breast cancer cells is about tenfold higher than in quiescent breast cancer cells12 and that σ2 receptor 
expression is up-regulated during the transition from quiescence to proliferation and down-regulated 
during the transition from proliferation to quiescence.13 Consequently, σ2 receptor density has been 
proposed as a tool to determine the proliferative status of tumours.23 Most significantly, selective 2 
receptor ligands e.g. SV119 2 (Figure 1) were shown to not only bind to these tumour cells, but also 
induce apoptosis in a dose-dependent fashion in vitro and in vivo.13,14 Furthermore, 2 expression has 
been linked to tumour cell proliferation.15  
 
Although the exact mechanism for the modulation of the signalling pathways downstream of σ2 
receptors leading to cancer cell death is not known, they are thought to involve changes in cytosolic 
calcium and sphingolipid signalling.16 Furthermore, σ2 receptor ligands may have a potential role in the 
treatment of tumours17 while specific radiolabelled σ2 receptor ligands can be used to image tumour 
cell proliferation in vivo using positron emission tomography (PET) or single-photon emission 
computed tomography (SPECT).18 
 
The σ2 receptor has not been cloned and its structure has not been determined. However, recently, the 
σ2 receptor, was identified as the progesterone receptor membrane component 1 (Pgrmc1) using photo-
affinity studies and a σ2 ligand containing both a photoactive azide moiety and a fluorescein 
isothiocyanate group for protein visualisation.19 This protein was also found to be up-regulated in 
multiple types of cancer and shown that Pgrmc1 is required for tumour cell proliferation, motility and 
tumour formation in vivo. Furthermore, small molecule inhibitors of Pgrmc1, such as AG-205 (5, 
Figure 1), suppressed the growth of lung, breast and cervical cancer cell lines.20  
 
A number of structurally-diverse compounds have been shown to possess high affinity to σ receptors.21 
However, most of these compounds were shown to bind selectively to the σ1 receptor or have similar 
affinities to both σ1 and σ2 receptors. Some early σ2 selective ligands reported in the literature include 
the benzomorphan-7-one analogue CB-64D (3)22, the 3-(ω-aminoalkyl)-1H-indole analogue Lu 28-179 
(siramesine, 4)23, ibogaine24, and the tropane analogue WC-59 (6).25 These, and later σ2 ligands, have 
been recently comprehensively reviewed.26 
 
Fig. 1 Selected examples of σ2 ligands with their corresponding σ1 activities and the sigma selectivity index between the 
two targets. The tetrahydroisoquinolylamide 1 was the starting point for this project. 
 
SAR studies based on a series of conformationally-flexible benzamide analogues, initially developed 
as D3-selective ligands,
27d,e,f produced a class of compounds having a high affinity for σ2 receptors and 
excellent σ2:σ1 selectivity ratios.
27 A key development in this series of compounds was the presence of 
a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline ring. This not only resulted in compounds having a 
high affinity and excellent selectivity for σ2 versus σ1 receptors, but dramatically reduced their affinity 
 
for dopamine receptors. Further modifications, including the incorporation of fluorescent and 
radiolabelled probes produced molecules, e.g. WC-59 (6) with significant 2 affinity and selectivity.28 
These σ2 selective ligands have subsequently been used to directly identify, locate and quantify this 
protein using a variety of receptor-binding and molecular imaging techniques.29 
 
Molecules based on the conformationally-flexible benzamide 1 have proven to be an important source 
of σ2-selective compounds. Preliminary work has shown that having a conformationally flexible spacer 
unit of four carbon atoms was beneficial for σ2 binding affinity and selectivity.
27a However, limited 
work was undertaken on the effects of substitutions on the carboxylic acid and no work had been 
performed to observe what effect restricting conformational freedom has on σ2 receptor activity in this 
class. Further, little work has been conducted on varying the substitution pattern of the methoxy 
groups on the tetrahydroisoquinoline ring, although, it has been shown that either opening the 
tetrahydroisoquinyl ring or replacing the methoxy groups with methylene-, ethylene- and 
propylenedioxy rings decrease the σ2 activity.
27b,30 Despite these results, there remains considerable 
scope for further modifications to this structure for the preparation of radiolabeled probes to image this 
receptor in vitro and in vivo. In this study, the effect of modulating the conformational freedom of the 
spacer, varying the carboxylic acid substitution on the amide and modifying the methoxy substitution 
on the tetrahydroisoquinolyl ring was investigated with the purpose of expanding the scope of 
analogues synthesised and evaluated to produce a candidate that was suitable for radiolabelling with 
SPECT and PET isotopes. 
Results and discussion 
Chemistry 
Using the tetrahydroisoquinoline benzamide 1 as our lead compound, we synthesised a series of 
analogues and tested them as selective σ2 ligands. Therefore, the substituted piperidines 7-9 were Boc 
N-protected (10-12), followed by the incorporation of a leaving group using standard chemistry 
(Scheme 1). The addition of the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline unit under SN2 reaction 
conditions (16-18) followed by N-deprotection yielded the secondary amines 19-21 which underwent 
coupling with a variety of aromatic carboxylic acids to produce target tetrahydroisoquinolylamides 22 
- 32. Additionally, the use of variously substituted benzofuran-2-carboxylic acids yielded ligands 33 - 
39. The synthesis of target ligands with more flexible central linkers (Scheme 2) started with the 
alkylation of tetrahydroisoquinolines with bromonitriles of varying lengths (40 - 46) followed by 
LiAlH4 reduction to the corresponding primary amines 47 - 53. Coupling of the amines to 5-bromo- or 
































































































































































Scheme 1 Reagents: a) di-tert-butyldicarbonate, CH2Cl2, b) PPh3, I2, imidazole, c) 6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline hydrochloride, TBAI, K2CO3, DMF, d) CH2Cl2/TFA (2:1), e) EDC, HOBt, DMF, R-COOH, f) 
EDC, HOBt, DMF, 5-substituted-benzofuran-2-carboxylic acids. 
 
Scheme 2 Reagents: a) Br(CH2)nCN, TBAI, K2CO3, DMF, b) LiAlH4, THF, c) EDC, HOBt, DMF 
Discussion 
All synthesised ligands were tested for their σ1 and σ2 activities, their σ2 selectivities determined and 
their CLogP calculated (Tables 1-3). The first series of compounds synthesised investigated the use of 
a conformationally restricted linker by incorporating a six membered ring into the central chain - it 
also varied the terminal aromatic moiety, including the use of both aromatic carbocycles and 
heterocycles. Changing from the aromatic amide as in 22 to the benzofuran amide substitution of 33 
gave a more selective and active compound (σ2 = 44 nM, σ1/σ2 = 7.30) when compared to 22. 
Compounds 23 and 24 were synthesised to observe the effects of changing the heteroatom from an 
oxygen, to a nitrogen 23 or sulphur 24. The compounds were still selective for the σ2 receptor (σ1/σ2 = 
4.2 and 0.98 respectively); however, the benzofuran 33 remained the better derivative. Changing to the 
 
larger 1-naphthyl (28), the 3-quinolyl (26) or the styryl (25) derivatives substantially weakened the 
activity. Changing the point of attachment for various heterocycles (e.g. indole C6 or C3) resulted in 
some of the weakest activity observed. However, adding a substituent to indole C5 resulted in 
increasing activity across the range. Translating this result to the ‘best’ terminal moiety, the 2-
benzofuran with the addition of C5 bromo (34) improved the activity by an order of magnitude (σ2 = 
8.7 nM, σ1/σ2 = 292). The use of an iodo substituent (35) was not as effective (σ2 = 11.0 nM, σ1/σ2 = 
62.0). Starting from the bromobenzofuran derivative 34, and extending the linker by one methylene 
(36) and two methylene units (37) resulted in slight improvements in activity but at a significant 
expense to selectivity. 
 
The lead compound 1 had a flexible four carbon linker and a bromodimethoxyphenyl ring at the 
terminus. The incorporation of the restricted linker and the methylpiperidine core (22) decreased 
activity and selectivity for the σ2 receptor (σ2 = 367 nM, σ1/σ2 = 5.9) compared to the lead 1. Given the 
best terminal aromatic group was a bromobenzofuran, the corresponding flexible linker versions were 
synthesised (54-59). Surprisingly the C5-iodosusbtituted benzofuran 59 produced the best outcome (σ2 
= 0.88 nM, σ1/σ2 = 886) with an order of magnitude better σ2 activity and the best selectivity over σ1 
that we have seen. 
 
Our final series of analogues investigated examined the removal of one of the tetrahydroisoquinoline 
methoxy substitutents and the size of the flexible linker (60-63). While significant activity was noted 
for the monomethoxy derivative 61, the selectivity was notably reduced. 
 
Therefore, the optimal ligand for σ2 activity and selectivity was the iodobenzofuran 59 containing a 
benzofuran carboxamide moiety with a halogen substitution at C5 and a 6,7-
dimethoxytetrahydroisoquinoline separated by a six carbon flexible spacer. This possessed a σ2 activity 
of 0.88 nM with a selectivity index of 886. On the other hand, the best ligand for σ1 activity was 61 
with a value of 76 nM and a σ2 value of 4.4 nM. This relatively poor activity for σ1 was still 
significantly better than most other derivatives and also still possessed better σ2 activity. Therefore, the 
σ2 activity for this series, along with the consistently good selectivity values can be seen as significant 
and consistent and validates pursuing this extended SAR study. 
 
Table 1 σ1 and σ2 binding affinities (Ki) for benzamides. 
 
 n CLog P 
σ2 Ki  
(nM) 
σ1 Ki  
(nM) 
σ1/σ2 
22 1 3.16 367 ± 1.0 2180 ± 54 5.90 
23 1 3.29 88 ± 5 372 ± 11 4.20 
24 1 3.38 97 ± 2 95 ± 1 0.98 
25 1 3.05 137 ±7  818 ± 6 5.97 
26 1 2.38 283 ± 2 82 ± 7.5 0.29 
27 1 2.77 845 ±15 164 ± 5 0.19 
28 1 3.08 115 ± 9 475 ± 34 4.13 
29 1 2.76 752 ± 23 130 ± 12 0.17 
30 1 4.20 40 ± 12 3863 ± 153 97 
31 1 3.51 44 ± 5 77 ± 11 1.80 
32 1 3.63 160 ± 15 395 ± 39 2.20 
33 1 3.22 44 ± 7.0 322 ± 56 7.30 
34 1 3.96 8.7 ± 0.6 2545 ± 103 292 
35 1 4.25 11.0 ± 1.2 682 ± 181 62.0 
36 2 3.99 4.9 ± 1.2 360 ± 41 73.0 
37 3 4.02 5.3 ± 0.2 209 ± 21 39.0 
38 2 3.83 10.6 ± 1.1 184 ± 2 17.0 
39 3 3.36 12.4 ± 0.9 97.9 ± 8.0 7.9 
 
 
Table 2 σ1 and σ2 binding affinities (Ki) for benzamides. 
 






54 Br 1 3.63 15.0 ± 1.4 3718 ± 650 248 
55 Br 2 3.81 6.2 ± 0.4 410 ± 18.5 66.1 
56 Br 3 3.94 8.0 ± 0.1 157 ± 2 19.6 
57 I 1 3.82 6.2 ± 1.2 752 ± 148 121 
58 I 2 3.91 8.9 ± 2.1 204 ± 10 22.9 
59 I 3 4.47 0.88 ± 0.5 780 ± 127 886 
 
Table 3 σ1 and σ2 binding affinities (Ki) for benzamides. 
 






60 OMe H 1 4.08 133 ± 3 1277 ±52 9.6 
61 OMe H 2 4.31 4.4 ± 1.3 76 ±16 17.3 
62 H OMe 1 4.33 35 ± 5.3 616 ±12 17.6 
63 H OMe 2 4.43 31 ± 1.3 241 ±33 7.8 
 
Figure 2 shows a summary of the structure-activity results that have emerged from this study. Of the 
great variety of terminal aromatic moieties investigated, the benzofuran was the most potent, 
particularly with the presence of a C5-iodo substituent. The central linker is best if flexible and is 
optimal at six methylenes. Although the dimethoxy substituted tetrahydroisoquinoline exhibits good in 
vitro activity with just one methoxy substituent, it does at the expense of selectivity and appears to be 
optimal with 2 methoxy substituents present. 
 
 
Fig. 2 Structure and activity relationships for the tetrahydroisoquinolines with pendent aromatics as σ2 selective ligands 
Conclusion 
 
A series of tetrahydroisoquinolyl benzamides were synthesised and tested for their binding affinities to 
both σ1 and σ2. We have shown that this class of derivatives can be highly potent and selective for the 
σ2 receptor, with the piperidine based core favoured in most cases. The halogenated benzofuran 
derivatives 34 (Ki σ1/σ2 = 292) and 35 (Ki σ1/σ2 = 62.0) displaying good affinity and selectivity and 
increasing the conformational freedom produced more σ2 active derivatives. However, this also 
decreased σ2 selectivity in all cases except for that of 59 (ki σ1/σ2 = 886). Removal of the methoxy 
groups from the isoquinoline ring did not produce a more selective or high affinity ligand than that 
seen for compound 59, and these results corroborate the need to have a flexible linker with a 6,7-
dimethoxy isoquinyl ring substitution for optimum σ2 binding affinity. In addition, structural features 
were identified that result in extremely poor affinity and selectivity for both the σ1 and σ2 receptor 
subtypes. Therefore, the new information from our study offers a useful guide for designing σ2 specific 
compounds and promising new lead compounds 34 and 59 were produced, that show highly active σ2 
activity with significant selectivity, and have the potential to be utilised in future SPECT 
radiochemistry studies. 
Experimental 
Chemistry - general considerations 
All reagents purchased were used without further purification. Air sensitive reactions were performed 
under a positive pressure of nitrogen gas. THF and Et2O were distilled from sodium under nitrogen 
gas. Petroleum ether (PE) of boiling point range 40-60 oC was used. Melting points were recorded on a 
Gallenkamp (Griffin) melting point apparatus with temperatures reported in degrees Celsius (oC) and 
are uncorrected. NMR spectra were performed on a Bruker Advance DPX 400 operating at 400 MHz 
for 1H NMR spectra and 100 MHz for 13C NMR spectra. Electron impact and electrospray mass 
spectra were obtained using a Shimadzu QP-5000 GC-MS spectrometer by direct insertion technique 
with a 70 eV electron beam and high resolution on a VG Autospec spectrometer. Ion mass to charge 
(m/z) values are stated and their relative abundances as a percentage in parentheses. [3H] Pentazocine 
and [3H] DTG were purchased from Perkin-Elmer Life Sciences (Boston, MA, USA). 
 
The lipophilicity was assessed using RP-HPLC by determining the log P value using literature 
procedures.31 Samples, dissolved in methanol, were analyzed using a Waters, Xterra C18 column (5 
μm, 4.6 mm × 150 mm) with a mobile phase consisting of methanol/phosphate buffer (0.1 M, pH 7.5) 
and a flow rate of 1 mL/min. The log P of a studied compound was estimated by a comparison of its 
retention time to that of compounds of known log P value. 
 
Preparation of Compounds 16-18 
To a solution of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (1.0 eq), K2CO3 (4 eq) 
and TBAI (0.1 eq) in DMF (20 mL) was added the appropriate piperidine 13, 14, or 15 (1.0 eq). The 
solution was allowed to stir at rt for 3 days. The solution was diluted with EtOAc (100 mL) and 
extracted with H2O (3 x 20 mL), sat. NaHCO3 (25 mL), brine (25 mL) and H2O (20 mL). The organic 
layers were combined, dried (Na2SO4) and the organic solvent removed. The residue was subjected to 




Clear oil, yield 78%; 1H NMR (CDCl3) δ 1.10-1.14 (m, 2H), 1.45 (s, 9H), 1.76-1.80 (m, 3H), 2.33 (m, 
2H), 2.67-2.80 (m, 6H), 3.52 (s, 2H), 3.83 (s, 6H), 4.08-4.10 (bs, 2H), 6.52 (s, 1H), 6.59 (s, 1H). 13C 
NMR δ 28.6, 28.8, 34.1, 35.2, 37.2, 44.2, 51.5, 56.06, 56.08, 56.4, 64.4, 79.4, 109.7, 111.6, 126.4, 
126.8, 147.4, 147.7, 155.1. MS-ES+ m/z 391 (MH+, 100%); HRMS-ES+ calculated for C22H34N2O4: 
391.2586, found 391.2597. 
 tert-Butyl-4-(2-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)ethyl)piperidine-1-carboxylate 
[17] 
Clear oil, yield 62%; 1H NMR (CDCl3) δ 1.12-1.24 (m, 2H), 1.45 (s, 9H), 1.49-1.70 (m, 5H), 2.52 (t, 
2H, J = 8.0 Hz), 2.66-2.71 (m, 2H), 2.81 (t, 2H, J = 5.8 Hz), 3.53 (s, 2H), 3.83 (s, 3H), 3.84 (s, 3H), 
4.06-4.15 (m, 2H), 6.51 (s, 1H), 6.59 (s, 1H). 13C NMR δ 28.6, 28.7, 32.4, 34.0, 34.5, 44.2, 51.2, 55.8, 
56.0, 56.1, 64.3, 79.4, 109.7, 111.6, 126.3, 126.9, 147.4, 147.5, 156.0. MS-EI m/z 404 (M+, 8), 206 




Clear oil that solidified upon standing (mp 86-89 oC), yield 59%; 1H NMR (CDCl3) δ 1.06-1.09 (m, 
2H), 1.25-1.29 (m, 2H), 1.30-1.44 (m, 1H), 1.42 (s, 9H), 1.58-1.67 (m, 4H), 2.46 (t, 2H, J = 7.9 Hz), 
2.65-2.69 (m, 4H), 2.80 (t, 2H, J = 8.0 Hz), 3.52 (s, 2H), 3.81 (s, 3H), 3.82 (s, 3H), 4.06-4.11 (m, 2H), 
6.50 (s, 1H), 6.57 (s, 1H). 13C NMR (CDCl3) δ 24.5, 28.6, 28.7, 32.3, 34.5, 44.1, 51.2, 55.9, 56.01, 
56.04, 58.6, 79.3, 109.6, 111.5, 126.3, 126.7, 147.3, 147.7, 155.0. MS-ES+ m/z 419 (MH+, 35), 265 
(100%); HRMS-ES+ calculated for C24H39N2O4: 419.2910, found 419.2919. 
 
Preparation of compounds 19-21 
A solution of 16, 17 or 18 in CHCl2:TFA (10 mL, 2:1) was stirred for 30 min at rt. The product was 
basified with aq. K2CO3 (1 M, 200 mL) followed by aq. KOH (0.1 M, 50 mL) and extracted with 
CH2Cl2 (3 x 100 mL). The organic layers were combined, dried (Na2SO4) and the solvent removed to 
yield 19, 20 or 21 which were used without further purification. 
 
 1,2,3,4-Tetrahydro-6,7-dimethoxy-2-((piperidine-4-yl)methyl)isoquinoline [19] 
Yellow oil, yield 78%; 1H NMR (CDCl3) δ 1.11-1.15 (m, 2H), 1.72-1.80 (m, 3H), 2.32 (m, 2H), 2.58-
2.68 (m, 4H), 2.75-2.81 (m, 2H), 3.06-3.09 (m, 2H), 3.51 (s, 2H), 3.83 (s, 6H), 6.51 (s, 1H), 6.58 (s, 
1H). 13C NMR δ 28.8, 32.4, 34.3, 46.7, 51.5, 56.1, 56.5, 65.2, 109.7, 111.6, 126.5, 127.1, 147.3, 147.6. 
MS-ES+ m/z 291 (MH+, 40), 208 (100%); HRMS-EI calculated for C17H26N2O2: 290.1994, found 
290.1996. 
 1,2,3,4-Tetrahydro-6,7-dimethoxy-2-(2-(piperidin-4-yl)ethyl)isoquinoline [20] 
Cream solid, mp 102-103 oC, yield 83%; 1H NMR (CDCl3) δ 1.16-1.54 (m, 5H), 1.69-1.78 (m, 2H), 
2.50-2.69 (m, 6H), 2.80 (bs, 2H), 3.06 (bd, 2H, J = 9.8 Hz), 3.53 (s, 2H), 3.82 (s, 6H), 6.52 (s, 1H), 
6.58 (s, 1H). 13C NMR δ 29.0, 33.7, 34.8, 34.9, 46.8, 51.4, 56.0, 56.20, 56.22, 109.8, 111.7, 126.5, 
127.0, 147.5, 147.8. MS-ES+ m/z 305 (MH+, 100%); HRMS-EI calculated for C18H28N2O2: 304.2151, 
found 304.1391. 
 1,2,3,4-Tetrahydro-6,7-dimethoxy-2-(3-(piperidin-4-yl)propyl)isoquinoline [21] 
Clear oil, yield 94%; 1H NMR (CDCl3) δ 1.12-1.30 (m, 5H), 1.56-1.71 (m, 4H), 2.45 (t, 2H, J = 7.7 
Hz), 2.58-2.62 (m, 2H), 2.67 (t, 2H, J = 6.1 Hz), 2.80 (t, 2H, J = 5.8 Hz), 3.08 (bd, 2H, J = 12.0 Hz), 
3.51 (s, 2H), 3.810 (s, 3H), 3.813 (s, 3H), 6.49 (s, 1H), 6.57 (s, 1H). 13C NMR (CDCl3) δ 24.3, 28.7, 
32.8, 34.8, 35.9, 46.2, 51.1, 55.88, 55.92, 58.6, 109.6, 111.4, 126.3, 126.7, 147.2, 147.5. MS-EI m/z 
318 (M+, 26), 206 (100%); HRMS-EI calculated for C19H30N2O2: 318.2307, found 318.2305.  
 
Preparation of compounds 22-38 
To a stirred solution of the appropriate benzoic acid (1.0 eq) in anhydrous DMF (10 mL) was added, 
EDC (1.3 eq), HOBt (1.1 eq), and DIPEA (3.0 eq) and the reaction mixture was stirred at room 
temperature. After 5 min, a solution of the amine 19, 20 or 21 (1.0 eq) was added to this reaction 
mixture, and then was stirred at room temperature for 2 days under N2. The reaction mixture was 
diluted with EtOAc (80 mL), washed with H2O (3 x 25 mL), sat. Na2CO3 (15 mL), H2O (20 mL) and 
brine (15 mL). The organic layer was dried (Na2SO4) and solvent removed. The residue was subjected 




Prepared as white solid (250 mg, 41%) from 5-bromo-3,4-dimethoxycarboxylic acid27, mp 51-52 oC; 
1H NMR (DMSO) δ 1.09-1.19 (m, 2H), 1.68-1.71 (bd, 2H, J = 12.4 Hz), 1.90-1.96 (m, 1H), 2.35 (d, 
2H, J = 8.0 Hz), 2.64 (t, 2H, J = 5.4 Hz), 2.74 (t, J = 5.6 Hz), 3.05 (bs, 2H), 3.49 (s, 2H), 3.737 (s, 3H), 
3.742 (s, 3H), 3.75 (s, 3H), 3.89 (s, 3H), 4.51 (bs, 2H), 6.65 (s, 1H), 6.68 (s, 1H), 6.94-6.98 (m, 1H), 
7.27 (s, 1H). 13C NMR (DMSO) δ 29.0, 30.8, 34.0, 47.3, 51.8, 56.43, 56.45, 56.47, 57.1, 64.2, 111.2, 
113.0, 116.5, 117.2, 121.4, 121.7, 126.9, 127.7, 147.9, 148.1, 154.1, 165.1. MS-ES+ m/z 534 (MH+, 
100%); HRMS-EI calculated for C26H33
79BrN2O5: 533.1651, found 533.1683. 
 (4-((3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)methylpiperidin-1-yl)(1H-inden-2-
yl)methanone [33] 
White solid, mp 128-129 oC, yield 30%; 1H NMR (DMSO) δ 1.10-1.20 (m, 2H), 1.80-1.84 (bs, 2H), 
1.93 (m, 1H), 2.31 (d, 2H, J = 8 Hz), 2.60 (t, 2H, J = 6 Hz), 2.69 (t, J = 5.5 Hz), 3.03 (bs, 2H), 3.44 (s, 
2H), 3.680 (s, 3H), 3.684 (s, 3H), 4.28 (bs, 2H), 6.60 (s,1H), 6.63 (s, 1H), 7.27-7.32 (m, 2H), 7.40 (m, 
1H), 7.61 (d, 1H, J = 8.3 Hz), 7.70 (d, 1H, J = 7.8 Hz). 13C NMR (CDCl3) δ 29.0, 31.4, 34.0, 44.1, 
51.7, 55.9, 56.0, 56.4, 64.1, 110.6, 111.2, 112.4, 113.0, 123.0, 124.3, 126.8, 126.9, 127.5, 127.6, 147.9, 
148.1, 149.6, 154.6, 159.6. MS: LRMS m/z (ES+) 435 [MH]+ (100%); HRMS: calculated for 




White solid, mp 208-210 oC, yield 48%; 1H NMR (DMSO) δ 1.16-1.26 (m, 2H), 1.88 (bd, 2H, J = 12.3 
Hz), 1.96-2.03 (m, 1H), 2.38 (d, 2H, J = 7.2 Hz), 2.67 (t, 2H, J = 5.9 Hz), 2.76 (t, 2H, J = 5.3 Hz), 3.09 
(bs, 2H), 3.52 (s, 2H), 3.74 (s, 3H), 3.75 (s, 3H), 4.47 (bs, 2H), 6.67 (s, 1H), 6.70 (s, 1H), 6.77 (s, 1H), 
7.07 (t, 1H, J = 7.2 Hz), 7.20 (t, 1H, J = 7.2 Hz), 7.45 (d, 1H, J = 8.2 Hz), 7.62 (d, 1H, J = 8.0 Hz). 13C 
NMR (DMSO) δ 29.0, 31.5, 34.1, 44.1, 51.8, 56.41, 56.44, 64.3, 104.1, 111.2, 112.7, 113.0, 120.3, 
121.9, 123.7, 126.9, 127.6, 127.7, 131.2, 136.6, 147.8, 148.1, 162.7. MS-ES+ m/z 434 (MH+, 100%); 
HRMS-EI calculated for C26H31N3O3: 433.2365, found 433.2356. 
 (Benzo[b]thiophen-2-yl)(4-((3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)methyl)piperidin-
1-yl)methanone [24] 
Off-white solid, mp 80-82 oC, yield 41%; 1H NMR (DMSO) δ 1.17-1.27 (m, 2H), 1.87 (bd, 2H, J = 
12.2 Hz), 1.97-2.02 (m, 1H), 2.37 (d, 2H, J = 7.2 Hz), 2.66 (t, 2H, J = 6.1 Hz), 2.75 (t, J = 5.5 Hz), 
3.09 (bs, 2H), 3.51 (s, 2H), 3.74 (s, 3H), 3.75 (s, 3H), 4.32 (bs, 2H), 6.66 (s, 1H), 6.69 (s, 1H), 7.45-
7.46 (m, 2H), 7.70 (s, 1H), 7.94-7.97 (m, 1H), 8.02-8.04 (m, 1H). 13C NMR (DMSO) δ 29.0, 31.4, 
34.0, 45.6, 51.8, 56.4, 56.5, 64.2, 111.2, 113.0, 123.2, 125.5, 125.52, 125.53, 126.4, 126.9, 127.7, 
138.1, 139.4, 140.0, 147.9, 148.1, 163.1. MS-ES+ m/z 451 (MH+, 100%); HRMS-EI calculated for 
C26H30N2O3S: 450.1977, found 450.1974. 
 (E)-1-(4-((3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)methyl)piperidin-1-yl)-3-
phenylprop-2-en-1-one [25] 
White solid, mp 149-150 oC, yield 46%; 1H NMR (DMSO) δ 1.00-1.11 (m, 2H), 1.83 (bd, 2H, J = 12.3 
Hz), 1.90-1.95 (m, 1H), 2.35 (d, 2H, J = 7.1 Hz), 2.65 (t, 2H, J = 6.0 Hz), 2.75 (t, J = 5.4 Hz), 3.11 (bs, 
2H), 3.50 (s, 2H), 3.74 (s, 3H), 3.75 (s, 3H), 4.38 (bs, 2H), 6.66 (s, 1H), 6.69 (s, 1H), 7.24 (d, 1H, J = 
15.5 Hz), 7.37-7.46 (m, 3H), 7.49 (d, 1H, J = 15.5 Hz), 7.70-7.73 (m, 2H). 13C NMR (DMSO) δ 29.0, 
31.4, 34.1, 44.1, 51.8, 56.4, 64.3, 111.2, 113.0, 119.6, 126.9, 127.7, 128.6, 129.4, 130.0, 136.1, 141.7, 
147.9, 148.1, 165.1. MS-ES+ m/z 421 (MH+, 31), 443 (MHNa)+ (100%); HRMS-EI calculated for 
C26H32N2O3: 420.2413, found 420.2401. 
 (4-((3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)methyl)piperidin-1-yl)(quinolin-3-
yl)methanone [26] 
Orange solid, mp 70-72 oC, yield 48%; 1H NMR (DMSO) δ 1.19-1.29 (m, 2H), 1.85 (bd, 2H, J = 12.3 
Hz), 1.96-2.00 (m, 1H), 2.38 (d, 2H, J = 7.1 Hz), 2.66 (t, 2H, J = 5.9 Hz), 2.75 (t, 2H, J = 5.4 Hz), 3.07 
(bs, 2H), 3.50 (s, 2H), 3.739 (s, 3H), 3.742 (s, 3H), 4.51 (bs, 2H), 6.66 (s, 1H), 6.69 (s, 1H), 7.69-7.73 
(m, 1H), 7.85-7.89 (m, 1H), 8.10 (m, 2H), 8.44 (d, 1H, J = 2.1 Hz), 8.92 (d, 1H, J = 2.1 Hz). 13C NMR 
(DMSO) δ 29.0, 31.2, 34.0, 47.5, 51.8, 56.43, 56.46, 64.2, 111.2, 113.0, 126.9, 127.4, 127.6, 128.0, 
129.3, 129.5, 130.2, 131.2, 134.8, 147.9, 148.1, 148.3, 149.2, 167.4. MS-ES+ m/z 446 (MH+, 100%); 
HRMS-ES+ calculated for C27H31N3O3: 446.2444, found 446.2454. 
 (4-((3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)methyl)piperidin-1-yl)(1H-indol-6-
yl)methanone [27] 
Light brown solid, mp 210-213 oC, yield 42%; 1H NMR (DMSO) δ 1.13-1.23 (m, 2H), 1.80-1.83 (m, 
2H), 1.92-1.97 (m, 1H), 2.38 (d, 2H, J = 7.2 Hz), 2.66 (t, 2H, J = 6.2 Hz), 2.75 (t, 2H, J = 5.6 Hz), 
2.94-3.00 (m, 2H), 3.51 (s, 2H), 3.74 (s, 3H), 3.75 (s, 3H), 4.15-4.24 (m, 2H), 6.51 (d, 1H, J = 2.9 Hz), 
6.66 (s, 1H), 6.69 (s, 1H), 7.05 (dd, 1H, J = 8.1 Hz, 1.3 Hz), 7.47 (m, 2H), 7.61 (s, 1H). 13C NMR 
(DMSO) δ 30.0, 32.4, 35.0, 44.6, 52.7, 57.1, 57.3, 57.6, 65.4, 102.8, 111.7, 112.2, 113.4, 119.6, 121.3, 
127.6, 128.4, 128.7, 130.0, 130.6, 136.7, 148.5, 148.8, 171.9. MS-ES+ m/z 434 (MH+, 100%); HRMS-
ES+ calculated for C26H31N3O3: 434.2444, found 434.2450.  
  (4-((3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)methyl)piperidin-1-yl)(naphthalen-1-
yl)methanone [28] 
White solid, mp 58-60 oC, yield 35%; 1H NMR (DMSO) δ 1.10-1.30 (m, 2H), 1.60-1.70 (m, 1H), 1.90-
1.97 (m, 2H), 2.36 (m, 2H), 2.64 (t, 2H, J = 5.7 Hz), 2.73 (t, J = 5.6 Hz), 2.93-3.10 (m, 2H), 3.48 (s, 
2H), 3.732 (s, 3H), 3.736 (s, 3H), 4.69 (bs, 2H), 6.64 (s, 1H), 6.68 (s, 1H), 7.40-7.50 (m, 1H), 7.56-
7.63 (m, 3H), 7.76-7.83 (m, 1H), 7.97-8.03 (m, 2H). 13C NMR (DMSO) δ 29.0, 31.1, 34.1, 47.6, 51.8, 
56.46, 56.49, 56.5, 64.2, 111.2, 113.0, 124.1, 125.4, 126.1, 126.9, 127.1, 127.6, 127.7, 129.1, 129.3, 
133.8, 135.7, 147.9, 148.2, 168.6. MS-ES+ m/z 445 (MH+, 100%); HRMS-ES+ calculated for 
C28H32N2O3: 445.2491, found 445.2488. 
 (3a,7a-Dihydro-1H-indol-3-yl)(4-((3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-
yl)methyl)piperidin-1-yl)methanone [29] 
Off-white solid, mp 206-207 oC, yield 39%; 1H NMR (DMSO) δ 1.13–1.23 (m, 2H), 1.81–1.84 (m, 
2H), 1.95-2.03 (m, 1H), 2.37 (d, 2H, J = 6.2 Hz), 2.66 (t, 2H, J = 5.9 Hz), 2.74 (t, 2H, J = 5.5 Hz), 
 
2.98-3.04 (m, 2H), 3.51 (s, 2H), 3.74 (s, 6H), 4.29-4.33 (m, 2H), 6.66 (s, 1H), 6.69 (s, 1H), 7.13 (t, 1H, 
J = 7.1 Hz), 7.19 (t, 1H, J = 7.1 Hz), 7.47 (d, 1H, J = 8.1 Hz), 7.64 (d, 1H, J = 2.4 Hz), 7.69 (d, 1H, J = 
7.8 Hz). 13C NMR (DMSO) δ 28.1, 30.7, 33.3, 44.4, 50.9, 55.52, 55.54, 56.9, 63.5, 110.3, 110.4, 
111.7, 112.1, 119.8, 119.9, 121.5, 125.8, 126.0, 126.8, 127.1, 135.5, 147.0, 147.2, 165.3. MS-ES+ m/z 
434 (MH+, 100%); HRMS-ES+ calculated for C26H31N3O3: 434.2454, found 434.2444.  
 (5-Bromobenzofuran-2-yl)(4-((3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-
yl)methyl)piperidin-1-yl)methanone [34] 
Prepared as white solid using 5-bromobenzo[b]furan-2-carboxylic acid32, mp 75-78 oC, yield 40%; 1H 
NMR (DMSO) δ 1.15-1.23 (m, 2H), 1.84-1.88 (m, 2H), 1.97-2.01 (m, 1H), 2.35 (d, 2H, J = 7.1 Hz), 
2.64 (t, 2H, J = 6.2 Hz), 2.73 (t, J = 5.6 Hz), 3.06 (m, 2H), 3.49 (s, 2H), 3.717 (s, 3H), 3.723 (s, 3H), 
4.29 (m, 2H), 6.63 (s, 1H), 6.67 (s, 1H), 7.31 (s, 1H), 7.56-7.59 (m, 1H), 7.65 (d, 1H, J = 1.9 Hz), 7.95 
(d, 1H, J = 7.9 Hz). 13C NMR (DMSO) δ 29.0, 31.6, 34.0, 48.2, 51.8, 56.44, 56.46, 56.47, 64.1, 110.0, 
111.2, 113.0, 114.5, 116.6, 125.4, 126.9, 127.7, 129.6, 129.8, 147.9, 148.1, 150.8, 153.5, 159.2. MS-EI 
m/z 512 (M+, 7), 206 (100%); HRMS-EI calculated for C26H29
79BrN2O4: 512.1311, found 512.1309. 
 (5-Bromo-1H-indol-2-yl)(4-((3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)methyl)piperidin-
1-yl)methanone [30] 
White solid, mp 212-214 oC, yield 27%; 1H NMR (DMSO) δ 1.15-1.26 (m, 2H), 1.89 (bd, 2H, J = 12.3 
Hz), 1.98-2.03 (m, 1H), 2.38 (d, 2H, J = 7.1 Hz), 2.67 (t, 2H, J = 6.3 Hz), 2.76 (t, 2H, J = 5.6 Hz), 3.09 
(bs, 2H), 3.51 (s, 2H), 3.74 (s, 3H), 3.75 (s, 3H), 4.42 (bs, 2H), 6.66 (s, 1H), 6.70 (s, 1H), 6.76 (s, 1H), 
7.31 (dd, 1H, J = 8.7, 1.9 Hz), 7.42 (d, 1H, J = 8.6 Hz), 7.82 (d, 1H, J = 1.9 Hz). 13C NMR (DMSO) δ 
29.0, 31.4, 34.1, 46.0, 51.8, 56.45, 56.46, 64.2, 103.5, 111.2, 112.8, 113.0, 114.7, 124.1, 126.3, 126.9, 
127.7, 129.5, 132.7, 135.3, 147.9, 148.1, 162.2. MS-ES+ m/z 511.8 (MH+, 75), 230 (100%); HRMS-
ES+ calculated for C26H30
79BrN3O3: 512.1549, found 512.1532. 
 (4-Bromo-3-methylphenyl)(4-((3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-
yl)methyl)piperidin-1-yl)methanone [31] 
White solid, mp 50-51 oC, yield 55%; 1H NMR (DMSO) δ 1.09-1.19 (m, 2H), 1.77-1.84 (m, 2H), 1.92-
1.98 (m, 1H), 2.35 (d, 2H, J = 7.1 Hz), 2.41 (s, 3H), 2.65 (t, 2H, J = 6.0 Hz), 2.74 (t, J = 5.6 Hz), 2.93–
3.04 (m, 2H), 3.50 (s, 2H), 3.73 (s, 3H), 3.74 (s, 3H), 4.05 (bs, 2H), 6.65 (s,1H), 6.69 (s, 1H), 7.15 (dd, 
1H, J = 8.2, 2.1 Hz), 7.38 (s, 1H), 7.66 (d, 1H, J = 8.1 Hz). 13C NMR (DMSO) δ 22.9, 29.0, 31.2, 34.0, 
47.5, 51.7, 56.36, 56.38, 64.2, 111.1, 113.0, 125.6, 126.6, 126.9, 127.7, 130.0, 132.8, 136.8, 138.3, 
147.8, 148.1, 168.6. MS-ES+ m/z 488 (MH+, 100%); HRMS-EI calculated for C25H31
79BrN2O3: 
487.1596, found 487.1581. 
 (5-Bromo-1H-indol-3-yl)(4-((3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)methyl)piperidin-
1-yl)methanone [32] 
Off-white solid, mp 215-217 °C, yield 38%; 1H NMR (DMSO) δ 1.07-1.18 (m, 2H), 1.78 (bd, 2H, J = 
10.9 Hz), 1.89-1.94 (m, 1H), 2.32 (d, 2H, J = 7.1 Hz), 2.61 (t, 2H, J = 6.1 Hz), 2.71 (t, 2H, J = 5.3 Hz), 
2.98 (bt, 2H, J = 11.4 Hz), 3.46 (s, 2H), 3.700 (s, 3H), 3.703 (s, 3H), 4.26 (bd, 2H, J = 11.1 Hz), 6.61 
(s, 1H), 6.65 (s, 1H), 7.26 (dd, 1H, J = 8.6, 1.9 Hz), 7.40 (d, 1H, J = 8.6 Hz), 7.68 (s, 1H), 7.82 (d, 1H, 
J = 1.9 Hz). 13C NMR (DMSO) δ 28.1, 30.6, 33.3, 44.4, 50.9, 55.5, 55.6, 56.7, 63.4, 109.7, 110.2, 
112.0, 112.6, 113.7, 122.3, 124.2, 126.0, 126.7, 128.0, 128.5, 134.3, 146.9, 147.2, 164.5. MS-EI m/z 
512 (M+, 100%); HRMS-EI calculated for C26H31N3O3
79Br: 512.1549, found 512.1542.  
 (4-((3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)methyl)piperidin-1-yl)(5-iodobenzofuran-
2-yl)methanone [35]  
Prepared from 5-iodobenzo[b]furan-2-carboxylic acid33 as a clear film, yield 42%; 1H NMR (CDCl3) δ 
1.23-1.30 (m, 2H), 1.93-2.03 (m, 3H), 2.39 (d, 2H, J = 6.4 Hz), 2.51 (m, 2H), 2.70 (t, 2H, J = 6.0 Hz), 
2.82-2.95 (m, 2H), 3.54 (s, 2H), 3.83 (s, 3H), 3.84 (s, 3H), 4.36-4.66 (m, 2H), 6.52 (s, 1H), 6.60 (s, 
1H), 7.14 (s, 1H) 7.27 (d, 1H, J = 8.4 Hz), 7.63 (dd, 1H, J = 8.8, 2.0 Hz), 7.97 (d, 1H, J = 2.0 Hz). 13C 
NMR (CDCl3) δ 28.8, 30.8, 34.3, 43.5, 47.3, 51.6, 56.07, 56.09, 56.5, 64.2, 87.1, 109.6, 110.1, 111.6, 
114.0, 126.4, 126.8, 129.9, 131.1, 135.0, 147.4, 147.7, 150.3, 154.0, 159.5. MS-ES+ m/z 561.2 (MH+, 
100%); HRMS-ES+ calculated for C26H30N2O4I: 561.4236, found 561.4240. 
 5-Bromobenzofuran-2-yl)(4-(2-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-
yl)ethyl)piperidin-1-yl)methanone [36] 
White solid, mp 92-95 oC, yield 51%; 1H NMR (DMSO) δ 1.16-1.24 (m, 2H), 1.49 (q, 2H, J = 7.2 Hz), 
1.67-1.70 (m, 1H), 1.79 (bd, 2H, J = 12.5 Hz), 2.45-2.51 (m, 2H), 2.60 (t, 2H, J = 6.0 Hz), 2.70 (t, 2H, 
J = 5.5 Hz), 3.00 (bs, 2H), 3.45 (s, 2H), 3.69 (s, 3H), 3.70 (s, 3H), 4.25 (bs, 2H), 6.62 (s, 1H), 6.64 (s, 
1H), 7.28 (s, 1H), 7.48 (d, 1H, J = 8.8 Hz), 7.60 (dd, 2H, J = 8.8, 2.0 Hz), 7.94 (d, 1H, J = 2.0 Hz). 13C 
NMR (DMSO) δ 28.2, 31.9, 32.8, 33.4, 50.6, 54.6, 54.9, 55.1, 55.51, 55.54, 109.1, 110.2, 112.0, 113.7, 
115.7, 124.6, 126.0, 126.8, 128.7, 128.9, 146.9, 147.2, 149.9, 152.6, 158.3. MS-ES+ m/z 528 (MH+, 
 
100%); HRMS-ES+ calculated for C27H32N2O4
79Br: 528.6352, found 528.6360.  
 (5-Bromobenzofuran-2-yl)(4-(3-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-
yl)propyl)piperidin-1-yl)methanone [37] 
White foam, mp 62-64 oC, yield 36%; 1H NMR (CDCl3) δ 1.23-1.29 (m, 4H), 1.62-1.66 (m, 3H), 1.82 
(bd, 2H, J = 11.7 Hz), 2.47-2.51 (m, 2H), 2.70 (t, 2H, J = 6.1 Hz), 2.82 (t, 2H, J = 5.8 Hz), 3.20 (bs, 
2H), 3.55 (s, 2H), 3.825 (s, 3H), 3.832 (s, 3H), 4.52 (bd, 2H), 6.51 (s, 1H), 6.58 (s, 1H), 7.15 (s, 1H), 
7.31 (d, 1H, J = 8.7 Hz), 7.46 (dd, 2H, J = 8.8, 2.0 Hz), 7.76 (d, 1H, J = 1.9 Hz). 13C NMR (CDCl3) δ 
21.6, 24.0, 32.2, 33.4, 35.8, 43.4, 49.1, 52.1, 54.8, 56.1, 56.2, 109.4, 110.6, 111.4, 113.5, 116.7, 118.2, 
122.6, 124.8, 129.1, 129.4, 148.8, 149.4, 150.5, 153.3, 159.4. MS-ES+ m/z 542 (MH+, 100%); HRMS-
EI calculated for C26H33N2O4
79Br: 541.1689, found 541.1693. 
 (4-(2-(3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)ethyl)piperidin-1-yl)(5-iodobenzofuran-
2-yl)methanone [38] 
Brown wax, yield 50%; 1H NMR (CDCl3) δ 1.22-1.29 (m, 2H), 1.57-1.59 (m, 2H), 1.79 (m, 1H), 1.82 
(bd, 2H, J = 11.7 Hz), 2.55 (t, 2H, J = 8.0 Hz), 2.69 (t, 2H, J = 6.4 Hz), 2.81 (t, 2H, J = 5.6 Hz), 3.13 
(bs, 2H), 3.54 (s, 2H), 3.820 (s, 3H), 3.824 (s, 3H), 4.58 (bd, 2H), 6.51 (s, 1H), 6.58 (s, 1H), 7.13 (s, 
1H), 7.27 (d, 1H, J = 8.9 Hz), 7.63 (dd, 1H, J = 8.8, 2.0 Hz), 7.96 (d, 1H, J = 1.2 Hz). 13C NMR 
(CDCl3) δ 14.8, 28.9, 32.9, 33.7, 34.5, 44.6, 47.3, 51.2, 55.6, 55.9, 56.0, 87.1, 109.6, 110.3, 111.5, 
113.9, 126.2, 126.6, 129.8, 131.0, 134.9, 147.3, 147.7, 150.2, 153.9, 159.3. MS-EI m/z 574 (M+, 39), 
206 (100%); HRMS-EI calculated for C27H31N2O4I: 574.4526, found 574.4530. 
 (4-(3-(3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)propyl)piperidin-1-yl)(5-
iodobenzofuran-2-yl)methanone [39] 
White solid, yield 43%, mp 162-163 °C; 1H NMR (CDCl3) δ 1.23-1.29 (m, 4H), 1.62-1.66 (m, 1H), 
1.82 (m, 4H), 2.87-3.20 (m, 8H), 3.83 (s, 3H), 3.85 (s, 3H), 4.06 (s, 2H), 4.50 (bd, 2H), 6.52 (s, 1H), 
6.61 (s, 1H), 7.14 (s, 1H), 7.28 (d, 1H, J = 1.7 Hz), 7.63 (dd, 1H, J = 8.7, 1.8 Hz), 7.96 (d, 1H, J = 1.7 
Hz). 13C NMR (CDCl3) δ 25.5, 29.8, 32.9, 33.6, 35.6, 43.6 , 49.6, 53.4, 56.09, 56.14, 60.5, 87.1, 109.5, 
110.2, 111.4, 114.0, 124.3, 129.8, 129.9, 131.1, 135.0, 147.9, 148.3, 150.2, 154.0, 159.4. MS-EI m/z 
588 (M+, 42), 341 (100%); HRMS-EI calculated for C28H33N2O4I: 588.1301, found 588.1289. 
 
Preparation of compounds 40-46 
To a solution of the appropriate nitrile derivative (1 eq) in DMF (20 mL) was added either 6,7-
dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (1 eq), or 6-methoxy-1,2,3,4-
tetrahydroisoquinoline hydrochloride34 (1 eq), or 7-methoxy-1,2,3,4-tetrahydroisoquinoline 
hydrochloride (1 eq), followed by K2CO3 (4 eq), TBAI (0.1 eq) and KI (0.01 eq) and the solution 
stirred for 16 h. The reaction mixture was then diluted with EtOAc (100 mL) and extracted with H2O 
(3 x 20 mL), sat. NaHCO3 (25 mL), brine (25 mL) and H2O (20 mL). The organic layers were 
combined, dried (Na2SO4) and the organic solvent removed. The residue was purified column 
chromatography (EtOAc:MeOH, 9:1). 
 
 4-(3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butanenitrile27 [40] 
White solid, mp 106-108 °C, yield 85%; 1H NMR (CDCl3) δ 2.47 (t, 2H, J = 7.1 Hz), 2.62 (t, 2H, J = 
6.7 Hz), 2.70 (t, 2H, J = 6.1 Hz), 2.81 (t, 2H, J = 5.8 Hz), 3.54 (s, 2H), 3.83 (s, 3H), 3.84 (s, 3H), 6.51 
(s, 1H), 6.59 (s, 1H,). MS-EI m/z 260 (M+, 42), 164 (100%).  
 5-(3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)pentanenitrile [41] 
Clear oil, yield 83%; 1H NMR (CDCl3) δ 1.73-1.77 (m, 4H), 2.39 (t, 2H, J = 6.6 Hz), 2.53 (t, 2H, J = 
6.6 Hz), 2.69 (t, 2H, J = 6.0 Hz), 2.81 (t, 2H, J = 5.8 Hz), 3.54 (s, 2H), 3.83 (s, 3H), 3.84 (s, 3H), 6.52 
(s, 1H), 6.59 (s, 1H). 13C NMR (CDCl3) δ 17.2, 23.5, 26.0, 28.6, 51.0, 55.8, 55.99, 56.02 57.0, 109.6, 
111.5, 119.8, 126.2, 126.4, 147.4, 147.6. MS-EI m/z 274 (M+, 33), 206 (100%); HRMS-EI calculated 
for C16H22N2O2: 274.3206, found 274.3210.  
 6-(3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)hexanenitrile [42] 
Red oil, yield 86%; 1H NMR (CDCl3) δ 1.73-1.77 (m, 4H), 2.40-2.42 (m, 2H), 2.52-2.55 (m, 2H), 2.69 
(t, 2H, J = 6.0 Hz), 2.81 (t, 2H, J = 5.8 Hz), 3.54 (s, 2H), 3.83 (s, 3H), 3.84 (s, 3H), 6.52 (s, 1H), 6.59 
(s, 1H). 13C NMR (CDCl3) δ 17.2, 23.5, 25.9, 26.0, 28.6, 51.0, 52.3, 55.7, 56.0, 57.0, 109.6, 111.5, 
119.8, 126.2, 126.4, 147.4, 147.7. MS-EI m/z 288 (M+, 2), 206 (100%); HRMS-EI calculated for 
C17H24N2O2: 288.6578, found 288.6583. 
 4-(3,4-Dihydro-6-methoxyisoquinolin-2(1H)-yl)butanenitrile [43] 
White solid. yield 76%, from 6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride33; 1H NMR 
(CDCl3) δ 1.92 (pentet, 2H, J = 6.9 Hz), 2.47 (t, 2H, J = 7.1 Hz), 2.62 (t, 2H, J = 6.7 Hz), 2.71 (t, 2H, J 
= 6.1 Hz), 2.87 (t, 2H, J = 5.8 Hz), 3.55 (s, 2H), 3.77 (s, 3H), 6.63 (d, 1H, J = 2.6 Hz), 6.70 (dd, 1H, J 
= 8.4, 2.6 Hz), 6.92 (d, 1H, J = 8.4 Hz). 13C NMR (CDCl3) δ 15.0, 23.3, 29.5, 51.0, 55.4, 55.6, 56.2, 
 
112.3, 113.4, 120.0, 126.8, 127.6, 135.5, 158.2. MS-EI m/z 230 (M+, 28), 176 (100%); HRMS-EI 
calculated for C14H18N2O: 230.1340, found 230.1334.  
 5-(3,4-Dihydro-6-methoxyisoquinolin-2(1H)-yl)pentanenitrile [44] 
White solid, yield 61%; 1H NMR (CDCl3) δ 1.73-1.76 (m, 4H), 2.39-2.42 (m, 2H), 2.51-2.55 (m, 2H), 
2.69 (t, 2H, J = 6.0 Hz), 2.87 (t, 2H, J = 5.8 Hz), 3.54 (s, 2H), 3.77 (s, 3H), 6.63 (d, 1H, J = 2.6 Hz), 
6.71 (dd, 1H, J = 8.4, 2.7 Hz), 7.01 (d, 1H, J = 8.4 Hz). 13C NMR (CDCl3) δ 17.2, 23.5, 26.1, 29.5, 
51.0, 55.3, 55.8, 57.2, 112.2, 113.3, 119.8, 127.0, 127.6, 135.5, 158.1. MS-EI m/z 244 (M+, 23), 176 
(100%); HRMS-EI calculated for C15H20N2O: 244.1497, found 244.1497. 
 4-(3,4-Dihydro-7-methoxyisoquinolin-2(1H)-yl)butanenitrile [45] 
White solid, yield 77%; 1H NMR (CDCl3) δ 1.91 (pentet, 2H, J = 6.9 Hz), 2.45 (t, 2H, J = 7.1 Hz), 
2.63 (t, 2H, J = 6.7 Hz), 2.71 (t, 2H, J = 6.1 Hz), 2.82 (t, 2H, J = 5.8 Hz), 3.59 (s, 2H), 3.77 (s, 3H), 
6.56 (d, 1H, J = 2.7 Hz), 6.72 (dd, 1H, J = 8.4, 2.7 Hz), 7.01 (d, 1H, J = 8.4 Hz). 13C NMR (CDCl3) δ 
15.0, 23.2, 28.3, 51.1, 55.4, 56.0, 56.3, 111.3, 112.7, 119.9, 126.4, 129.7, 135.6, 157.7. MS-EI m/z 230 
(M+, 74), 176 (100%); HRMS-EI calculated for C14H18N2O: 230.1419, found 230.1422.  
 5-(3,4-Dihydro-7-methoxyisoquinolin-2(1H)-yl)pentanenitrile [46] 
White solid, yield 59%; 1H NMR (CDCl3) δ 1.74-1.78 (m, 4H), 2.40-2.43 (m, 2H), 2.52-2.56 (m, 2H), 
2.60 (t, 2H, J = 6.0 Hz), 2.83 (t, 2H, J = 5.8 Hz), 3.59 (s, 2H), 3.78 (s, 3H), 6.56 (d, 1H, J = 2.6 Hz), 
6.71 (dd, 1H, J = 8.4, 2.7 Hz,), 7.01 (d, 1H, J = 8.4 Hz). 13C NMR (CDCl3) δ 17.2, 23.5, 26.1, 28.3, 
51.2, 55.4, 56.4, 57.1, 111.4, 112.7, 119.8, 126.5, 129.7, 135.7, 157.7. MS-EI m/z 244 (M+, 23), 176 
(100%); HRMS-EI calculated for C15H20N2O: 244.1576, found 244.1564.  
 
Preparation of compounds 47-53 
To a suspension of LiAlH4 (3 eq) in dry THF (50 mL) was added the appropriate nitrile (1 eq) in dry 
THF (25 mL) dropwise under a stream of N2. The resulting mixture was heated at reflux for 18 h under 
N2. To the cooled solution at 0 
oC was added iced H2O (5 mL) and 10% NaOH (15 mL). The solution 
was warmed to rt and allowed to stir for 15 min. The resulting suspension was filtered through celite 
and the filter cake washed with EtOAc (50 mL). The organic layer was dried (Na2SO4) and solvent 
removed to give 46-52 which were used without further purification. 
 4-(3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butan-1-amine [47] 
Yellow oil, yield 65%; 1H NMR (CDCl3) δ 1.49 (m, 2H), 1.62 (m, 2H), 2.49 (t, 2H, J = 8.0 Hz), 2.71 
(m, 4H), 2.80 (t, 2H, J = 5.6 Hz), 3.53 (s, 2H), 3.81 (s, 3H), 3.83 (s, 3H), 6.50 (s, 1H), 6.57 (s, 1H). 13C 
NMR (CDCl3) δ 25.0, 27.2, 30.6, 41.0, 53.1, 54.9, 56.0, 56.1, 58.9, 110.9, 112.5, 126.1, 129.1, 147.2, 
148.8. MS-ES+ m/z 265.1 (MH+, 100%); HRMS calculated for C15H24N2O2: 264.1838, found 
264.1832.  
 5-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)pentan-1-amine [48] 
Yellow oil, yield 62%; 1H NMR (CDCl3) δ 1.23-1.62 (m, 6H), 2.45-2.49 (m, 2H), 2.67-2.71 (m, 4H), 
2.80 (t, 2H, J = 5.9 Hz), 3.52 (s, 2H), 3.805 (s, 3H), 3.81 (s, 3H), 6.50 (s, 1H), 6.56 (s, 1H). 13C NMR 
(CDCl3) δ 25.0, 27.2, 28.7, 33.6, 42.0, 51.2, 55.9, 56.0, 56.02, 58.4, 109.6, 111.5, 126.3, 126.8, 147.3, 
147.6. MS-ES+ m/z 279 (MH+, 41), 181 (100%); HRMS-EI calculated for C16H26N2O2: 278.1994, 
found 278.1977. 
 6-(3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)hexan-1-amine [49] 
Yellow oil, yield 68%; 1H NMR (CDCl3) δ 1.22-1.46 (m, 8H), 1.58 (bs, 2H), 2.48 (t, 2H, J = 7.8 Hz), 
2.60-2.66 (m, 4H), 2.76 (t, 2H, J = 5.6 Hz), 3.48 (s, 2H), 3.77 (s, 3H), 3.78 (s, 3H), 6.51 (s, 1H), 6.57 
(s, 1H). 13C NMR (CDCl3) δ 26.9, 27.2, 27.5, 28.7, 33.5, 42.0, 51.1, 55.8, 55.9, 56.0, 58.4, 110.6, 
111.9, 126.8, 127.1, 147.6, 147.9. MS-ES+ m/z 293 (MH+, 50), 188 (100%); HRMS-EI calculated for 
C17H28N2O2: 292.2151, found 292.2144. 
 4-(3,4-Dihydro-6-methoxyisoquinolin-2(1H)-yl)butan-1-amine [50] 
Yellow oil, yield 94%; 1H NMR (CDCl3) δ 1.54-1.56 (m, 2H), 1.67 (m, 2H), 2.52 (t, 2H, J = 7.6 Hz), 
2.64-2.77 (m, 4H), 2.86-2.89 (m, 2H), 3.61 (s, 2H), 3.78 (s, 3H), 6.61 (d, 1H, J = 2.6 Hz), 6.68 (dd, 
1H, J = 8.4, 2.6 Hz), 6.90 (dd, 1H, J = 8.3, 2.8 Hz). 13C NMR (CDCl3) δ 24.6, 29.4, 31.7, 42.0, 50.9, 
55.2, 55.7, 58.3, 112.1, 113.2, 127.1, 127.5, 135.5, 157.9. MS-EI m/z 234 (M+, 1), 162 (100%); 
HRMS-EI calculated for C14H22N2O: 234.1654, found 234.1653.  
 5-(3,4-Dihydro-6-methoxyisoquinolin-2(1H)-yl)pentan-1-amine [51] 
Yellow oil, yield 95%; 1H NMR (CDCl3) δ 1.34-1.62 (m, 8H), 2.48 (t, 2H, J = 7.8 Hz), 2.67-2.70 (m, 
4H), 2.86 (t, 2H, J = 5.8 Hz), 3.54 (s, 2H), 3.75 (s, 3H), 6.61 (d, 1H, J = 2.4 Hz), 6.66 (dd, 1H, J = 8.4, 
2.5 Hz), 6.91 (d, 1H, J = 8.4 Hz). 13C NMR (CDCl3) δ 24.9, 27.1, 29.4, 33.6, 42.0, 51.0, 55.3, 55.7, 
58.5, 112.1, 113.2, 127.2, 127.5 , 135.5, 158.0. MS-EI m/z 248 (M+, 18), 42 (100%); HRMS-EI 
calculated for C15H24N2O: 248.3602, found 248.3612.  
 4-(3,4-Dihydro-7-methoxyisoquinolin-2(1H)-yl)butan-1-amine [52] 
 
Yellow oil, yield 89%; 1H NMR (CDCl3) δ 1.48-1.84 (m, 6H), 2.50 (t, 2H, J = 7.7 Hz), 2.71 (m, 4H), 
2.82 (t, 2H, J = 5.8 Hz), 3.59 (s, 2H), 3.76 (s, 3H), 6.55 (d, 1H, J = 2.5 Hz), 6.69 (dd, 1H, J = 8.4, 2.6 
Hz), 6.99 (d, 1H, J = 8.4 Hz) 13C NMR (CDCl3) δ 24.7, 28.3, 31.7, 42.1, 51.3, 55.3, 56.4, 62.4, 111.4, 
112.6, 126.5, 129.6, 135.9, 157.7. MS-EI m/z 234 (M+, 15), 162 (100%); HRMS-EI calculated for 
C14H22N2O: 234.1732, found 234.1737. 
 5-(3,4-Dihydro-7-methoxyisoquinolin-2(1H)-yl)pentan-1-amine [53] 
Yellow oil, yield 77%; 1H NMR (CDCl3) δ 1.35-1.63 (m, 6H), 1.79 (bs, 2H), 2.48 (t, 2H, J = 7.6 Hz), 
2.67-2.70 (m, 4H), 2.81 (m, 2H, J = 5.6 Hz), 3.57 (s, 2H), 3.75 (s, 3H), 6.54 (dd, 1H, J = 2.4 Hz), 6.68 
(dd, 1H, J = 8.4 Hz, 2.4 Hz), 6.98 (d, 1H, J = 8.4 Hz). 13C NMR (CDCl3) δ 24.9, 27.2, 28.3, 33.7, 42.2, 
51.3, 55.3, 56.5, 58.4, 111.4, 112.6, 126.6, 129.6, 136.0, 157.7. MS-EI m/z 248 (M+, 15), 32 (100%); 
HRMS-EI calculated for C14H22N2O: 248.3604, found 248.3609.  
 
Preparation of compounds 54-63 
Compounds 54-63 were prepared using the same method for compounds 22-39 
 5-Bromo-N-(4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl)-1-benzofuran-2-
carboxamide [54] 
Clear film, yield 23%; 1H NMR (CDCl3) δ 1.74 (m, 4H), 2.57 (t, 2H, J = 6.7 Hz), 2.74 (t, 2H, J = 6.2 
Hz), 2.83 (t, 2H, J = 5.6 Hz), 3.50 (dt, 2H, J = 5.8 Hz), 3.56 (s, 2H), 3.79 (s, 3H), 3.82 (s, 3H), 7.16 (s, 
1H), 7.18 (s, 1H), 7.25 (m, 2H), 7.38 (m, 1H), 7.43 (dd, 1H, J = 8.8, 2.0 Hz), 7.71 (d, 1H, J = 2.0 Hz). 
13C NMR δ 24.8, 27.3, 28.5, 39.4, 50.7, 55.9, 55.99, 56.00, 57.4, 109.2, 109.6, 111.5, 113.3, 116.7, 
125.2, 126.1, 126.2, 129.5, 129.6, 147.5, 147.8, 150.2, 153.4, 158.6. MS-ES+ m/z 488 (MH+, 100%); 
HRMS-ES+ calculated for C24H38N2O4
79Br: 488.3659, found 488.3652. 
 5-Bromo-N-(5-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)pentyl)-1-benzofuran-2-
carboxamide [55] 
Clear film, yield 23%; 1H NMR (CDCl3) δ 1.45-1.49 (m, 2H), 1.62-1.69 (m, 4H), 2.48 (t, 2H, J = 7.5 
Hz), 2.67 (t, 2H, J = 6.1 Hz), 2.78 (t, 2H, J = 5.6 Hz), 3.44-3.49 (m, 2H), 3.52 (s, 2H), 3.80 (s, 3H), 
3.81 (s, 3H), 6.49 (s, 1H), 6.55 (s, 1H), 6.74 (bt, 1H, J = 3.9 Hz), 7.26-7.35 (m, 2H), 7.46 (dd, 1H, J = 
8.8, 2.0 Hz), 7.75 (d, 1H, J = 2.0 Hz). 13C NMR (CDCl3) δ 24.8, 26.9, 28.7, 29.6, 39.4, 51.1, 55.87, 
55.92, 55.95, 58.1 , 109.4, 109.5, 111.4, 113.2, 116.7, 125.3, 126.2, 126.6, 129.6, 129.8, 147.2, 147.5, 
150.0, 153.4, 158.4. MS-ES+ m/z 502 (MH+, 100%); HRMS-ES+ calculated for C25H28N2O4
79Br: 
502.5639 found 502.5643. 
 5-Bromo-N-(6-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)hexyl)-1-benzofuran-2-
carboxamide [56] 
Clear film, yield 35%; 1H NMR (CDCl3) δ 1.39-1.46 (m, 4H), 1.61-1.68 (m, 4H), 2.48-2.54 (m, 2H), 
2.70 (t, 2H, J = 6.1 Hz), 2.81 (t, 2H, J = 5.8 Hz), 3.47 (m, 2H), 3.54 (s, 2H), 3.82 (s, 3H), 3.83 (s, 3H), 
6.50 (s, 1H), 6.58 (s, 1H), 6.62 (t, 1H, J = 5.3 Hz), 7.38 (m, 2H), 7.49 (dd, 1H, J = 8.8, 2.0 Hz), 7.80 
(d, 1H, J = 1.9 Hz). 13C NMR (CDCl3) δ 26.6, 27.1, 26.8, 27.8, 29.6, 39.5, 50.7, 55.2, 56.01, 56.04, 
57.6, 109.5, 109.6, 111.4, 113.4, 116.9, 125.2, 125.4, 129.6, 129.9, 131.2, 147.5, 147.9, 150.1, 153.5, 
158.5. MS-ES- m/z 513 (M-1, 100%); HRMS-ES- calculated for C26H30N2O4




White wax, yield 47%; 1H NMR (CDCl3) δ 1.73-1.74 (m, 4H), 2.55 (m, 2H), 2.71 (t, 2H, J = 6.0 Hz), 
2.82 (t, 2H, J = 5.6 Hz), 3.50 (m, 2H), 3.55 (s, 2H), 3.79 (s, 3H), 3.82 (s, 3H), 6.47 (s, 1H), 6.56 (s, 
1H), 7.05 (d, 1H, J = 8.7 Hz), 7.23 (s, 1H), 7.38 (m, 1H), 7.59 (d, 1H, J = 8.7 Hz,), 7.90 (s, 1H). 13C 
NMR (CDCl3) δ 24.9, 27.4, 28.6, 39.5, 50.7, 55.99, 56.02, 57.5, 87.2, 108.9, 109.6, 111.5, 113.8, 
126.2, 126.5, 130.2, 131.4, 135.2, 147.4, 147.7, 149.8, 154.0, 158.5. MS-ES+ m/z 535 (MH+, 100%); 
HRMS-EI calculated for C24H27N2O4I: 534.1016, found 534.1011. 
 5-Iodo-N-(5-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)pentyl)-1-benzofuran-2-
carboxamide [58] 
Brown wax, yield 30%; 1H NMR (CDCl3) δ 1.46-1.50 (m, 2H), 1.62-1.70 (m, 4H), 2.51 (m, 2H), 2.69 
(t, 2H, J = 6.2 Hz), 2.80 (t, 2H, J = 5.7 Hz), 3.48 (t, 2H, J = 7.0 Hz), 3.53 (s, 2H), 3.82 (s, 3H), 3.82 (s, 
3H), 6.50 (s, 1H), 6.56 (s, 1H), 6.71 (m, 1H), 7.22 (d, 1H, J = 8.7 Hz), 7.34 (s, 1H), 7.64 (dd, 1H, J = 
8.7, 1.8 Hz), 7.98 (d, 1H, J = 1.7 Hz). 13C NMR (CDCl3) δ 23.7, 24.9, 26.9, 28.7, 39.4, 51.1, 55.9, 
56.97, 57.00, 58.1, 87.2, 109.1, 109.6, 111.5, 113.7, 126.3, 126.7, 128.0, 131.5, 135.4, 147.3, 147.6, 
149.7, 154.0, 158.4. MS-ES+ m/z 549 (MH+, 100%); HRMS-ES+ calculated for C25H30N2O4I: 




Brown wax, yield 41%; 1H NMR (CDCl3) δ 1.41 (m, 4H), 1.62 (m, 4H), 2.48 (m, 2H), 2.68 (t, 2H, J = 
6.1 Hz), 2.80 (t, 2H, J = 5.7 Hz), 3.45 (t, 2H, J = 7.0 Hz), 3.53 (s, 2H), 3.81 (s, 3H), 3.82 (s, 3H), 6.50 
(s, 1H), 6.57 (s, 1H), 6.66 (m, 1H), 7.24 (d, 1H, J = 8.7 Hz), 7.35 (s, 1H), 7.65 (dd, 1H, J = 8.7, 1.8 
Hz), 7.98 (d, 1H, J = 1.7 Hz). 13C NMR δ 27.0, 27.2, 27.3, 28.7, 29.7, 39.5, 51.1, 55.9, 56.00, 56.02, 
58.4, 87.3, 109.2, 109.6, 111.5, 113.8, 126.3, 126.8, 130.4, 131.6, 135.5, 147.3, 147.6, 149.7, 154.1, 




White solid, mp 72-74 oC, yield 51%; 1H NMR (CDCl3) δ 1.74 (m, 4H), 2.56 (t, 2H, J = 6.6 Hz), 2.72 
(t, 2H, J = 6.0 Hz), 2.88 (t, 2H, J = 5.7 Hz), 3.50 (m, 2H), 3.58 (s, 2H), 3.76 (s, 3H), 6.61 (d, 1H, J = 
2.5 Hz), 6.69 (dd, 1H, J = 8.4, 2.6 Hz), 6.91 (d, 1H, J = 8.4 Hz), 7.06 (d, 1H, J = 8.7 Hz), 7.22 (s, 1H), 
7.40 (m, 1H), 7.60 (dd, 1H, J = 8.7, 1.7 Hz), 7.90 (d, 1H, J = 1.6 Hz). 13C NMR (CDCl3) δ 24.9, 27.4, 
29.4, 39.5, 50.6, 55.4, 55.9, 57.6, 87.2, 108.9, 112.3, 113.4, 113.8, 126.9, 127.6, 130.3, 131.5, 135.3, 
135.5, 149.8, 154.1, 158.1, 158.5 (CO). MS-ES+ m/z 505 (MH+, 100%); HRMS-ES+ calculated for 
C23H26N2O3I: 505.0988, found 505.0982. 
 5-Iodo-N-(5-(3,4-dihydro-6-methoxyisoquinolin-2(1H)-yl)pentyl)-1-benzofuran-2-carboxamide 
[61] 
Brown wax, yield 34%, 1H NMR (CDCl3) δ 1.47 (m, 2H), 1.66 (m, 4H), 2.50 (t, 2H, J = 6.7 Hz), 2.69 
(t, 2H, J = 5.6 Hz), 2.86 (t, 2H, J = 5.3 Hz), 3.47 (dt, 2H, J = 6.3 Hz), 3.54 (s, 2H), 3.76 (s, 3H), 6.61 
(s, 1H), 6.67 (m, 3H), 6.91 (d, 1H, J = 8.4 Hz), 7.23 (d, 1H, J = 8.7 Hz), 7.35 (s, 1H), 7.65 (d, 1H, J = 
8.7 Hz), 7.99 (s, 1H). 13C NMR (CDCl3) δ 24.9, 26.9, 29.5, 29.6, 39.5, 51.0, 55.3, 55.8, 58.3, 87.2, 
109.2, 112.1, 113.3, 113.8, 127.2, 127.6, 130.3, 131.6, 135.4, 135.6, 149.7, 154.1, 158.0, 158.4. MS-
ES+ m/z 519 (MH+, 100%); HRMS-ES+ calculated for C24H28N2O3I: 519.1145, found 519.1155. 
 5-Iodo-N-(4-(3,4-dihydro-7-methoxyisoquinolin-2(1H)-yl)butyl)-1-benzofuran-2-carboxamide 
[62] 
Brown wax, yield 30%; 1H NMR (CDCl3) δ 1.75-1.77 (m, 4H), 2.55-2.58 (m, 2H), 2.74 (t, 2H, J = 6.0 
Hz), 2.84 (t, 2H, J = 5.7 Hz), 3.51-3.53 (m, 2H), 3.62 (s, 2H), 3.76 (s, 3H), 6.53 (d, 1H, J = 2.6 Hz), 
6.72 (dd, 1H, J = 8.4, 2.7 Hz), 7.00-7.07 (m, 2H), 7.23 (s, 1H), 7.42-7.44 (m, 1H), 7.61 (dd, 1H, J = 
8.7, 1.8 Hz), 7.91 (d, 1H, J = 1.7 Hz). 13C NMR (CDCl3) δ 24.9, 27.4, 28.2, 39.4, 50.8, 55.4, 56.6, 
57.4, 87.2, 108.9, 111.4, 112.7, 113.8, 126.5, 129.7, 130.3, 131.5, 135.3, 135.7, 149.8, 154.1, 157.8, 




Brown wax, yield 36%; 1H NMR (CDCl3) δ 1.43-1.47 (m, 2H), 1.62-1.69 (m, 4H), 2.50 (t, 2H, J = 7.5 
Hz), 2.69 (t, 2H, J = 6.0 Hz), 2.80 (t, 2H, J = 5.7 Hz), 3.46 (m, 2H), 3.57 (s, 2H), 3.74 (s, 3H), 6.52 (d, 
1H, J = 2.5 Hz), 6.67 (dd, 1H, J = 8.4, 2.6 Hz), 6.75 (m, 1H), 6.96 (d, 1H, J = 8.4 Hz), 7.21 (d, 1H, J = 
8.7 Hz), 7.33 (s, 1H), 7.63 (dd, 1H, J = 8.7, 1.7 Hz), 7.96 (d, 1H, J = 1.7 Hz). 13C NMR (CDCl3) δ 
24.9, 26.8, 28.2, 29.6, 39.4, 51.2, 55.3, 56.4, 58.0, 87.2, 109.1, 111.4, 112.6, 113.8, 126.5, 129.6, 
130.3, 131.5, 135.4, 135.8, 149.7, 154.0, 157.7, 158.4. MS-ES+ m/z 519 (MH+, 100%); HRMS-ES+ 
calculated for C24H28N2O3I: 519.1145, found 519.1133.  
 
 Measurement of Biological Activity 
Competition binding assays for ligands at σ1 and σ2 receptors were performed using [
3H](+)-PTZ (σ1), 
[3H]DTG/500 nM (+)-PTZ (σ2) and membranes from fresh-frozen, male Sprague Dawley rat brains as 
previously described.35 The animal experiments were performed according to the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes and were approved by the Animal 
Care and Ethics Committee of Australian Nuclear Science and Technology Organisation. The animals 
were obtained from the Animal Resource Centre Pty Ltd (Perth, Australia). Receptor binding assays 
were performed in triplicate and repeated three independent experiments. IC50 values were calculated 
using Prism software and converted to their corresponding Ki values using Cheng-Prusoff equation
36, 
based on a Kd of 2.5 nM for [
3H](+)-PTZ and a Kd of 77 nM for [
3H]DTG.35 
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1-(tert-Butoxycarbonyl)-4-hydroxymethylpiperidineS1 [10]  
Solid, (6.70 g, 96 %) mp 70-72 oC, (lit55 73 oC); 1H NMR (CDCl3) δ 1.11-1.21 (m, 
2H), 1.47 (s, 9H), 1.61-1.75 (m, 3H), 2.69-2.75 (m, 2H), 3.00 (d, 2H, J = 8.0 Hz), 




4-(2-Hydroxyethyl)-piperidine-1-carboxylic acid tert-butyl esterS2 [11] 
Clear oil, (4.13 g, 93 %); 1H NMR (CDCl3): δ 1.08-1.12 (m, 2H), 1.43 (s, 9H), 1.47-
1.67 (m, 5H), 2.67 (t, 2H, J = 12.2 Hz), 3.68 (t, 2H, J = 6.5 Hz), 4.04-4.09 (m, 2H). 




4-(3-Hydroxypropyl)piperidine-1-carboxylic acid tert-butyl esterS3 [12] 
Clear oil, (17.52 g, 64 %); 1H NMR (CDCl3) δ 1.06-1.12 (m, 2H), 1.30-1.40 (m, 
3H), 1.45 (s, 9H), 1.51-1.62 (m, 2H), 1.65 (bs, 2H), 2.65 (m, 2H), 3.61 (t, 2H, J = 





1-(tert-Butoxycarbonyl)-4-(iodomethyl)piperidineS4 [13]  
Clear oil, (5.58 g, 88 %); 1H NMR (CDCl3) δ 1.05-1.16 (m, 2H), 1.42 (s, 9H), 1.51-
1.63 (m, 1H), 1.78 (bd, 2H, J = 12.8 Hz), 2.65 (bt, 2H, J = 12.8 Hz), 3.08 (d, 2H, J = 




4-(2-Iodoethyl)piperidine-1-carboxylic acid tert-butyl esterS5 [14] 
Clear oil (730 mg, 56 %); 1H NMR (CDCl3) δ 1.07-1.15 (m, 2H), 1.44 (s, 9H), 
1.57-1.66 (m, 3H), 1.76 (q, 2H, J = 7.1 Hz), 2.69 (bt, 2H, J = 12.6 Hz), 3.20 (t, 2H, 





















4-(3-Iodoethyl)piperidine-1-carboxylic acid tert-butyl esterS3 [15] 
Clear oil (8.62 g, 59 %); 1H NMR δ 1.05-1.13 (m, 2H), 1.29-1.38 (m, 3H) 1.43 (s, 
9H), 1.58-1.63 (m, 2H), 1.78-1.86 (m, 2H), 2.64 (bt, J = 12.2 Hz), 3.16 (t, 2H, J = 






To a solution of 7-methoxyisoquinolineS6 [53] (700 mg, 4.40 mmol) in freshly distilled and dried 
liquid ammonia (30 mL) and EtOH (5 mL) was added Na (700 mg, 30.4 mmol) in small pieces over 
5 min. The reaction was allowed to proceed for 1 h. The ammonia solution was then allowed to 
evaporate and to the residue was added ice H2O (200 mL) and extracted with EtOAc (150 mL). The 
organic layer was further washed with H2O (20 mL) and brine (20 mL). The organic layer was dried 
(MgSO4) and the organic solvent removed to yield a dark yellow oil. The oil was suspended in Et2O 
(50 mL) and made acidic by the addition of a solution of 4 M HCl in dioxane. The resulting 
suspension was filtered to yield [54] (585 mg, 81%) as an off-yellow solid, mp 250-253 oC. 1H 
NMR (DMSO) δ 2.91 (t, 2H, J = 6.1 Hz), 3.27 (t, J = 6.1 Hz), 3.72 (s, 3H), 4.16 (s, 2H), 6.80-8.83 
(m, 2H), 7.10 (bd, 1H, J = 8.2 Hz). 13C NMR (DMSO) δ 23.9, 40.7, 43.4, 55.1, 111.3, 113.8, 123.9, 
129.7, 130.0, 157.7. MS-EI m/z 163 (M+ free base, 43), 134 (100%); HRMS-EI C10H13NO: 
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4. 1H and 13C spectra for final compounds 22-39 and 54-63 
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